Home » Stocks » FDMT

4D Molecular Therapeutics, Inc. (FDMT)

Stock Price: $48.98 USD 3.10 (6.76%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
After-hours: $45.11 -3.87 (-7.90%) Jan 19, 4:25 PM
Market Cap 1.25B
Revenue (ttm) 16.62M
Net Income (ttm) -52.26M
Shares Out 25.23M
EPS (ttm) -2.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $48.98
Previous Close $45.88
Change ($) 3.10
Change (%) 6.76%
Day's Open 46.33
Day's Range 45.40 - 51.00
Day's Volume 208,213
52-Week Range 36.20 - 51.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GuruFocus - 4 weeks ago

Andreas Halvorsen (Trades, Portfolio) has revealed two new buys in 4D Molecular Therapeutics Inc. (NASDAQ:FDMT) and AbCellera Biologics Inc. (NASDAQ:ABCL), according to GuruFocus' Real-Time Pi...

Other stocks mentioned: ABCL
GlobeNewswire - 1 month ago

EMERYVILLE, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT), a clinical-stage gene therapy company harnessing the power...

GlobeNewswire - 1 month ago

EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT), a clinical-stage gene therapy company harnessing the power...

NASDAQ - 1 month ago

4D Molecular Therapeutics, a Phase 1/2 gene therapy biotech developing novel AAVs for ophthalmic diseases, raised the proposed deal size for its upcoming IPO on Thursday. The Emeryville, CA-ba...

NASDAQ - 2 months ago

4D Molecular Therapeutics, which is developing targeted gene therapies for multiple diseases, filed on Tuesday with the SEC to raise up to $75 million in an initial public offering.

SEC - 2 months ago

4D Molecular Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

About FDMT

4D Molecular Therapeutics operates as a clinical-stage gene therapy company that develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology, and pulmonology therapeutic areas. The company engages in developing 4D-125, which is in a Phase I/II clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase I clinical trial for the treatment of choroideremia; and 4D-310, which is in a Ph... [Read more...]

Industry
Biotechnology
IPO Date
Dec 11, 2020
CEO
David Kirn
Employees
78
Stock Exchange
NASDAQ
Ticker Symbol
FDMT
Full Company Profile

Financial Performance

In 2019, FDMT's revenue was $6.99 million, a decrease of -50.56% compared to the previous year's $14.13 million. Losses were -$49.31 million, 416.2% more than in 2018.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for FDMT is 44.00, which is a decrease of -10.17% from the latest price.

Price Target
$44.00
(-10.17% downside)